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In this study, we investigated the role of protein disulphide isomerase (PDI) in rapid 
metabolism of S-nitrosoglutathione (GSNO) and S-nitrosoalbumin (albSNO) and in NO 
delivery from these compounds into cells. Incubation of GSNO or albSNO (1 μM) with 
the megakaryocyte cell line MEG-01 resulted in a cell-mediated removal of each 
compound which was inhibited by blocking cell surface thiols with 5, 5’-dithiobis 2-
nitrobenzoic acid (DTNB) (100 μM) or inhibiting PDI with bacitracin (5 mM). GSNO, 
but not albSNO, rapidly inhibited platelet aggregation and stimulated cyclic GMP 
(cGMP) accumulation (used as a measure of intracellular NO entry). cGMP 
accumulation in response to GSNO (1 μM) was inhibited by MEG-01 treatment with 
bacitracin or DTNB, suggesting a role for PDI and surface thiols in NO delivery. PDI 
activity was present in MEG-01 conditioned medium, and was inhibited by high 
concentrations of GSNO (500 μM). A number of cell surface thiol-containing proteins 
were labelled using the impermeable thiol specific probe 3-(N-maleimido-propionyl) 
biocytin (MPB). Pretreatment of cells with GSNO resulted in a loss of thiol reactivity 
on some but not all proteins, suggesting selective cell surface thiol modification. 
Immunoprecipitation experiments showed that GSNO caused a concentration-
dependent loss of thiol reactivity of PDI. Our data indicate that PDI is involved in both 
rapid metabolism of GSNO and intracellular NO delivery and that during this process 
PDI is itself altered by thiol modification.  In contrast, the relevance of PDI-mediated 
albSNO metabolism to NO signalling is uncertain. 
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Abbreviations 
4-DP    4, 4'-dithiodipyridine 
ACD    acid citrate dextrose 
albSNO  S-nitrosoalbumin 
BCA   bicinchoninic acid 
DTNB   5, 5’-dithiobis (2-nitrobenzoic acid) 
GSH   glutathione 
GSNO   S-nitrosoglutathione 
HBS   HEPES buffered saline 
MPB    3-(N-maleimido-propionyl) biocytin 
PDI   protein disulphide isomerase 
PMSF    phenylmethylsulfonyl fluoride 
RSNO   S-nitrosothiol 














S-nitrosothiols (RSNOs) may serve as a reservoir of nitric oxide (NO) in biological 
systems and represent a class of NO donor with many potential clinical uses [1]. The 
potent and selective anti-platelet activity of some of these compounds has suggested 
that they may be particularly useful as anti-thrombotic agents [2].  
 
RSNOs produce antiplatelet activity either by releasing NO and stimulating guanylyl 
cyclase, or via cyclic GMP-independent mechanisms [3]. S-nitrosoglutathione (GSNO) 
releases NO only slowly, nevertheless it has the ability rapidly to inhibit platelet 
aggregation, in part through cyclic GMP-independent mechanisms [4]. Several studies 
have reported delivery of NO into cells via transnitrosation reactions, which involve 
transfer of NO+ from one thiol to another [5-7]. For protein RSNOs (such as S-
nitrosoalbumin) to mediate platelet inhibition, prior exchange of NO onto a low 
molecular weight thiol appears necessary [8, 9]. Free thiols are available on the platelet 
surface itself [10, 11] and S-nitrosation of these thiols may be a further possible 
pathway of anti-platelet action. However the relatively unfavourable kinetics of 
transnitrosation reactions [12] suggest that some enzyme mediated system is required 
for the process to occur sufficiently rapidly to mediate signalling events.  
 
A number of studies have documented the existence of enzyme-catalysed systems that 
facilitate delivery of NO from RSNO into cells, either by cell mediated metabolism or 
via amino acid transport systems [13]. These may be important both for mediating 
RSNO bioactivity and for enabling cells to deal with nitrosative stress during periods of 
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long-term exposure [14, 15]. For membrane-impermeable molecules such as GSNO, a 
cell surface enzyme such as γ-glutamyl transpeptidase (γ-GT) or protein disulphide 
isomerase (PDI) may act as a receptor or entry point for the delivery of the nitric oxide 
signal [16-18]. Both γ-GT [19] and PDI [20] have been shown to metabolise GSNO and 
mediate NO release. These metabolism studies, however, have generally been carried 
out using relatively high GSNO concentrations (high μM to mM range) and long time 
periods (minutes – hours) [21, 22]. The fact that GSNO inhibits platelet aggregation at 
very low concentrations (nM to low μM), and within seconds, suggests that its 
metabolism should be assessed over more relevant concentrations and time periods in 
order to understand its relevance to anti-platelet activity.  
 
We have previously shown rapid metabolism of GSNO by platelets and 
megakaryocytes and the involvement of extracellular thiols in this process [23]. Here 
we extend these studies to report the role of PDI in rapid metabolism of GSNO and S-
nitroso human serum albumin (albSNO) at concentrations relevant to most published 
pharmacological studies and the relevance of this metabolism to NO delivery. We also 
report the effects of these interactions on PDI activity and its thiol redox status.  
 
Experimental Procedures 
Materials and reagents  
Cell culture medium (RPMI-1640), phosphate buffered saline (PBS), penicillin, 
streptomycin and L-glutamine were obtained from Biowhittaker (Wokingham, UK). 
Foetal calf serum (FCS) was purchased from Biowest (Ringmer, UK), MPB from 
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Molecular Probes (Eugene, OR), BCA protein assay kit from Perbio Science (Cheshire, 
UK) and RL 90 antibody against PDI from Alexis Biochemicals (Nottingham, UK). 
Reagents for cGMP measurement by enzyme immunoassay, Western blot 
chemiluminescence detection, immunoprecipitation, and streptavidin horseradish 
peroxidase (HRP) were obtained from Amersham Biosciences (Chalfont St. Giles, UK). 
All other chemicals were purchased from Sigma (Poole, UK).  
 
Preparation of RSNO compounds 
GSNO and S-nitrosocysteine (cysNO) were prepared as previously described [4] by 
nitrosation under acid conditions. Briefly, equal volumes of either glutathione or 
cysteine (20 mM) and sodium nitrite (20 mM) were incubated in the presence of 100 
mM HCl on ice for 30 minutes in the presence of 1 mM EDTA. GSNO and cysNO were 
freshly prepared and stored in the dark on ice until used. Concentrations of GSNO and 
cysNO were estimated by absorbance at 334 nm using extinction coefficients of 0.85 
and 0.75 mM-1 cm-1, respectively. 
 
AlbSNO was prepared by nitrosation of free thiols present on albumin. CysNO (20 
mM) was incubated with albumin (1 mg/ml) in the dark for 1 hr. AlbSNO was then 
separated from low-molecular weight CysNO by passing it through Sephadex G-25 gel 
filtration column and collecting albumin fractions. The protein concentration of each 
fraction was measured by BCA protein kit and albSNO in each fraction was quantified 
using an NO electrode with reference to GSNO calibration curve. AlbSNO fractions 
were then pooled, quantified and stored at -20ºC until used.  
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Preparation of MEG-01 cell suspensions 
The megakaryocyte cell line MEG-01 [24] was obtained from ATCC (Manassas, VA) 
and grown in RPMI-1640 medium supplemented with 10% v/v foetal calf serum (FCS), 
50 IU/ml aqueous penicillin, 50 μg/ml streptomycin and 2 mM L-glutamine and 
incubated at 37ºC with a humidified atmosphere of 5% CO2. For experiments cells were 
suspended in HBS at a count of 3×109 l-1. 
 
Preparation of washed platelets 
Washed platelets were prepared from informed healthy volunteers who had not received 
any medication known to alter platelet function for at least 2 weeks before study. Blood 
was anticoagulated with ACD and processed within 1 hour of collection. Washed 
platelets were separated from platelet rich plasma as previously described [25] and 
platelet count was adjusted to 200×109 l-1 by suspending in HEPES buffered saline 
(HBS), containing NaCl (140 mM), KCl (2.7 mM), Glucose (5mM), BSA (1mg/ml), 
CaCl2 (1mM), MgCl2 (1 mM) and HEPES (10 mM) (pH 7.3). 
 
Cell mediated RSNO metabolism and effects of enzyme inhibitors 
Cell mediated RSNO metabolism was analysed by treatment of MEG-01 cells with 1 
μM GSNO or albSNO at 37ºC for 2 minutes, following which cells were centrifuged at 
8300g for 30 seconds and residual RSNO in the supernatant was measured either using 
the fluorescent agent diaminonaphthaline [26] or by an electrochemical assay using an 
NO electrode (WPI, Stevenage, UK) [27], calibrated against GSNO (0-2000 nM). 
Control experiments were performed in the absence of MEG-01 cells.  
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The effect of different enzyme inhibitors and surface thiol blocking agents on RSNO 
metabolism was further investigated by pre-treatment of MEG-01 cells for 30 minutes 
at 37ºC. Bacitracin (5 mM) and acivicin (100 μM) were used to block PDI and γ-GT 
respectively, and an impermeable thiol blocking agent, 5,5’-dithiobis(2-nitrobenzoic 
acid) (DTNB) (100 μM) was used to modify extracellular thiol groups. RSNO decay, 
occurring after two minutes incubation with MEG-01 cells, was then measured. 
 
Inhibition of platelet aggregation by RSNO  
Platelet aggregation was performed using washed platelets suspended in HBS. Platelets 
were incubated with GSNO and albSNO (both 1 μM) at 37ºC for 5 or 30 seconds prior 
to addition of thrombin (0.1 unit ml-1) to induce aggregation. Aggregation was then 
monitored turbidometrically for 2 minutes. Effects of RSNO compounds were assessed 
by comparison with control experiments carried out in the vehicle.  
 
Cyclic GMP accumulation in response to RSNO 
GSNO or albSNO (1 μM) was incubated with MEG-01 cells at 37ºC for 2 minutes, after 
which an equal volume of 20% v/v perchloric acid was added. Samples were then 
stored at –20ºC. Prior to measurement of cGMP, pH of the supernatants was corrected 
to 7.4 by addition of K3PO4 (0.54 M), after which samples were centrifuged to remove 
precipitate and cGMP measured by enzyme immunoassay. Experiments were performed 
following treatment of cells with acivicin (100 μM), bacitracin (5 mM), DTNB (100 
μM) or a vehicle control for 30 minutes prior to addition of NO donors.  
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PDI activity in cell supernatant 
PDI has been shown to be released from platelets into the surrounding medium [28]. To 
measure PDI activity in MEG-01 supernatant, PDI-catalysed reduction of insulin was 
measured using a turbidometric assay [20]. MEG-01 cells were centrifuged at 8300g for 
30 seconds to obtain supernatant for use in the insulin assay. Cell supernatant was 
added to insulin (250 μM) in the presence of glutathione (GSH) (500 μM) in HBS 
containing 2 mM EDTA, pH 7.0. The increase in turbidity was monitored at 650 nm 
over a period of 40 hours. PDI activity in the supernatant was also measured following 
the addition of GSNO (1 - 500 μM). 
 
Sulfhydryl labelling of intact MEG-01 cells  
Cell surface thiol-containing proteins were labelled using the impermeable thiol specific 
probe, 3-N-maleimidylpropionyl-biotin (MPB) as described by Essex et al. [11]. MEG-
01 cells were incubated with MPB (100 μM) for 30 minutes on a rotating wheel at room 
temperature. The labelling reaction was stopped by addition of GSH (200 μM) for 30 
minutes and excess GSH was quenched using iodoacetamide (400 μM) for 10 minutes. 
Cells were washed twice with HBS and resuspended in 0.5 ml of ice-cold 50 mM 
Tris/HCl buffer (pH 7.3) containing sucrose (250 mM), leupeptin (10 μM), PMSF (2 
mM ) and EDTA (2 mM). Cells were lysed with three freeze/thaw cycles and 
centrifuged at 900g for 10 minutes to remove debris. The protein concentration of each 
sample was measured using BCA protein assay kit. Non-reducing SDS sample buffer 
was added to the cell lysate and the sample analysed using 10% SDS PAGE. Samples 
were transferred to a nitrocellulose membrane and biotinylated proteins were detected 
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using streptavidin-horseradish peroxidase and a chemiluminescent substrate.  Negative 
control experiments were performed with MEG-01 cells by (1) omitting MPB, and (2) 
incubating cells with the thiol blocking agent 4,4’-dithiodipyridine (4-DP) (4 mM) for 
30 minutes at 37ºC prior to addition of MPB. In both cases, there was a complete 
abolition of thiol labelling. To assess the effect of GSNO on cell surface thiols MEG-01 
cells were incubated with GSNO (3.5 mM) prior to addition of MPB. 
 
Immunoprecipitation of MEG-01 surface PDI 
MEG-01 cells (3×109 l-1) were incubated for 30 minutes at 37ºC with GSNO (0 - 5 mM) 
and then washed once in HBS prior to labelling with MPB as described above. In 
experiments to investigate the reversibility of thiol modification, cells were exposed to 
glutathione (4mM) for 30 minutes after GSNO treatment. Cells were then washed twice 
prior to MPB labelling. The labelled MEG-01 cells were then treated with lysis buffer 
(0.15 M NaCl, 0.5% v/v Triton X-100, 0.05% v/v Tween 20, 10 µM leupeptin, 10 µM 
aprotinin, 2 mM phenylmethylsulfonyl fluoride, 5 mM EDTA and 10 mM Tris-HCl, pH 
8.0). Samples were pre-cleared by incubation for 60 minutes at 4ºC with a mixture of 
protein G plus protein A beads, followed by centrifugation to remove beads. 
Supernatant was incubated for 60 min at 4ºC on a rotating wheel with RL 90 mouse 
monoclonal anti-PDI antibody (4.2 µg ml-1) or isotype control antibody. Samples were 
then centrifuged at 12,000g for 30 min at 4ºC to remove debris, after which a mixture of 
protein G plus protein A beads was added and samples incubated for 1 hr at 4ºC on a 
rotator. Beads were then washed once in lysis buffer and twice in 50 mM Tris-HCl, pH 
8.0, resuspended in loading buffer and boiled for 2 minutes. Protein concentration of 
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each sample was measured and samples were then run on a 10% polyacrylamide gel, 
transferred to a nitrocellulose membrane and visualized using streptavidin-horseradish 
peroxidase and chemiluminescent substrate.   
 
Statistical Analysis 
Effects of various treatments on cyclic GMP accumulation and RSNO metabolism were 
analysed on log-transformed data by one-way ANOVA following by Student t test, 




Cell mediated RSNO metabolism and effects of inhibitors 
Cell-mediated RSNO decay was analysed by measuring the amount of residual RSNO 
in cell supernatant after incubation with MEG-01 cells.  Addition of GSNO or albSNO 
(1 μM) to suspensions of MEG-01 cells resulted in a loss of approximately 84 or 93 nM 
per 109 cells respectively after two minutes. Similar results were obtained whether 
RSNO quantification was performed by either fluorescence assay or NO electrode 
methods. Prior incubation of cells with DTNB (100 μM) (an impermeable thiol 
blocking agent) or bacitracin (5 mM) (an impermeable PDI blocking agent) 
significantly blocked cell-mediated removal of both GSNO (figure 1a) and albSNO 
(figure 1b). However, inhibition of γ-GT with acivicin (100 μM) failed to influence 
RSNO removal.   
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In separate experiments bacitracin and acivicin, at the stated concentrations, were 
shown to completely inhibit the activity of authentic PDI, measured by turbidometric 
assay using insulin [20] and γ-GT, measured by colorimetric assay using γ-glutamyl 
paranitroaniline (data not shown). Cell viability, measured by trypan blue exclusion, 
was unaffected by treatment of cells with bacitracin, acivicin or DTNB at the stated 
concentrations (data not shown).  
 
Inhibition of platelet aggregation by RSNO  
The rapidity of GSNO as an antiplatelet agent was examined by platelet aggregation 
studies. Pre-incubation of platelets with 1 μM GSNO for as little as 5 seconds was 
sufficient to almost completely inhibit thrombin induced platelet aggregation compared 
with control (figure 2). In contrast, albSNO inhibited platelet aggregation only 
minimally even after 30 seconds pre-incubation.   
 
Mechanism of intracellular NO delivery from GSNO 
Intracellular accumulation of cyclic GMP was analysed as a measure of NO entry from 
GSNO and albSNO. GSNO incubation with MEG-01 for two minutes resulted in a 
significant cGMP accumulation (figure 3a), whereas albSNO failed to stimulate cGMP 
generation. Both bacitracin and DTNB, but not acivicin, significantly inhibited cGMP 
accumulation in response to GSNO (p < 0.05) (figure 3b). Control experiments omitting 
NO donors showed no effect of the various inhibitors on cGMP levels in their own 
right.  
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Detection of PDI activity in cell supernatant 
PDI activity, detected using a turbidometric assay of insulin disulphide reduction was 
evident in MEG-01 cell supernatant. GSNO inhibited this activity, however very high 
concentrations were required to show this effect (figure 4).  
 
Cell surface thiol modification by GSNO 
Our experiments suggested that GSNO, but not albSNO, was capable of delivering NO 
into MEG-01 cells to provoke cGMP accumulation. This intracellular transfer of NO 
depended upon the availability of cell surface sulphydryls and active PDI. We therefore 
further examined the action of GSNO by measuring its effects on the redox state of 
MEG-01 membrane thiol proteins. Treatment of cells with MPB resulted in labelling of 
a number of thiol-containing proteins on the MEG-01 cell surface. Prior incubation of 
MEG-01 cells with GSNO (3.5 mM) resulted in a loss of thiol reactivity on several, but 
not all proteins (figure 5).   
 
Identification of PDI as a target for redox modification by GSNO 
To determine whether PDI is a one of the target proteins modified by GSNO, MEG-01 
cells were labelled with MPB and RL 90 anti-PDI antibody was then used to 
immunoprecipitate PDI. Pretreatment of MEG-01 cells with GSNO (0.5 – 5 mM) 
resulted in a loss of thiol labelling of PDI in a concentration dependent manner (figure 
6).  Subsequent treatment with GSH resulted in a restoration of thiol labelling, indicating 






Our study shows that cell surface thiols and protein disulphide isomerase are required 
for NO delivery from GSNO into MEG-01 cells. Both GSNO and albSNO were rapidly 
metabolized by MEG-01 cells, however there was a discrepancy between albSNO 
metabolism and its NO signalling function. We have demonstrated cell surface thiol 
modification by GSNO and identified PDI as one of the target proteins. This is 
consistent with previous suggestions that PDI-catalysed S-nitrosation of cell surface 
thiols is a mechanism of nitric oxide delivery from GSNO [5, 18].   
 
GSNO, an endogenous molecule which may act as a storage form of NO, is a potent 
inhibitor of platelet aggregation despite its slow release of free NO, and this paradox led 
us to analyse its rapid metabolism at therapeutically relevant concentrations. The human 
megakaryocyte cell line MEG-01 displays platelet-like properties such as surface 
expression of PDI and αIIbβ3 as well as NO-induced activation of guanylyl cyclase and 
these properties, together with its ready availability, led us to employ this cell line in 
our experiments. 
 
In most published studies of cell mediated GSNO metabolism, relatively high 
concentrations and long time periods have been employed, yet even at concentrations as 
low as 1 μM, inhibition of platelet aggregation is evident within seconds. It is therefore 
difficult to assess the relevance of such studies to the anti-platelet actions of GSNO. 
Here, we found that cell mediated decay of 1 μM GSNO was evident within two 
minutes. This rapid GSNO removal was significantly inhibited both by modification of 
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cell surface thiols with DTNB, and by inhibition of cell surface PDI with bacitracin. 
Exposure of cells to acivicin to block γGT failed to influence GSNO removal, 
indicating that cell surface thiols and PDI, but not γGT, are required for rapid 
metabolism of GSNO. This is consistent with recent literature demonstrating PDI 
mediated GSNO consumption by platelets [20] and suggests that GSNO consumption 
may be relevant to its anti-platelet function. Ramachandran et al. [18] have provided 
evidence that NO released from impermeable RSNO molecules by cell surface PDI 
reacts with oxygen within the hydrophobic environment of the lipid membrane to 
produce N2O3, which then nitrosates intracellular thiol-containing molecules. Our data 
indicate that this, or a similar, pathway may be involved in the delivery of NO from 
GSNO onto the haem group of soluble guanylyl cyclase so as to stimulate generation of 
cyclic GMP. PDI inhibitors blocked this cyclic GMP accumulation significantly but not 
completely, implying the existence of alternative pathways for NO delivery. 
 
In contrast, the fate of the removed fraction of albSNO, and its relevance to NO 
signalling, are not clear. We observed that albSNO was metabolized in a similar way to 
GSNO, yet failed to inhibit platelet aggregation or stimulate intracellular cGMP 
accumulation. This suggests a discrepancy between the metabolism phenomenon, and 
subsequent signalling events. It has been documented that NO delivery into cells from 
protein RSNO molecules, such as albSNO,  requires a prior transfer of NO to a low 
molecular weight thiol, via transnitrosation [8, 9]. Our experiments were performed in 
the absence of added thiol and this may explain why metabolism of albSNO was not 
accompanied by cGMP accumulation or inhibition of platelet aggregation.   
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The involvement of PDI in transferring NO across the plasma membrane raises the 
question of how this process affects the function of PDI itself. PDI activity is dependent 
on its vicinal free thiol groups at the active site [29] which themselves may act as a 
target for nitrosation. We studied changes brought about by GSNO in thiol redox state 
of MEG-01 cell surface proteins. Consistent with earlier reports [10, 11] a number of 
such proteins were detectable by western blotting using MPB, an impermeable thiol 
specific probe. Cell treatment with GSNO caused a loss of thiol reactivity on most, but 
not all, proteins suggesting a selective process of GSNO-mediated thiol redox 
modification. Thiol modification of PDI itself was demonstrated using 
immunoprecipitation with a specific antibody, and this was GSNO concentration-
dependent. Subsequent addition of GSH led to restoration of thiol labelling, indicating 
that the GSNO-mediated thiol modification was reversible. It has been discussed that in 
the presence of sulphydryl compounds S-nitrosated proteins can undergo either 
transnitrosation, to restore the reduced thiol state, or S-thiolation reactions, yielding 
disulphide and nitroxyl [30, 31]. Our results indicate that, under the conditions used, the 
former reaction was predominant. 
 
PDI is known to be present on the surface of platelets and to be released during platelet 
activation [28, 32]. We also found PDI activity to be released from MEG-01 cells, and 
inhibited by GSNO, again consistent with an earlier report [20]. Thus the involvement 
of PDI in mediating NO transfer results in thiol modification and enzyme inactivation. 
The mechanisms employed to restore the redox state of active site thiols in PDI 
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following interaction with GSNO are not yet clear. Burgess et al. [10] showed that the 
redox state of platelet surface PDI was refractory to extracellular reducing agents, but 
discussed the possibility that it might be controlled by a plasma membrane electron 
transfer system such as NAD(P)H oxidase. 
 
PDI activity was inhibited by interaction with GSNO, although high concentrations 
were required to show this effect. Our findings are consistent with those of Root et al. 
[20] who showed full inhibition of PDI was not achieved by GSNO at concentrations 
lower than 500 μM. We also found that very high concentrations of GSNO were needed 
to demonstrate PDI thiol modification. In view of the fact that GSNO suppresses 
platelet activation in the nanomolar to micromolar range, it is clear that further 
investigations will be required to establish the physiological relevance of these 
interactions. 
 
The integrin family of cell surface adhesive receptors mediates platelet aggregation by 
up-regulating their affinity state for ligand binding. Free thiols become available on the 
platelet surface upon activation [10] and those present on integrin αIIbβ3 provide a direct 
target for redox modification [33]. Thiol-disulphide exchange within αIIbβ3, catalysed 
by an endogenous isomerase activity [34], by PDI [11, 35], or by ERP5 [36] is 
necessary for transition to its active conformation. Thus the thiol redox state of αIIbβ3 
influences platelet adhesive function and any agent that modifies this redox state may 
interfere with platelet aggregation. Our data are consistent with a model in which 
GSNO mediates its actions by both cGMP-dependent and independent pathways. 
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Targeting of NO to cell surface free thiols facilitates its entry into cells and its 
interaction with soluble guanylyl cyclase to promote cGMP-dependent pathways. 
cGMP-independent actions may be mediated by thiol modification of surface targets 
such as PDI, thus inhibiting activation of αIIbβ3. This does not exclude other 
mechanisms of cGMP-independent action such as inhibition of intracellular calcium 
entry [37] or direct nitrosation of αIIbβ3 [33, 38].  
 
Overall, our data show that PDI is involved in the rapid metabolism of RSNOs and in 
NO delivery from GSNO to soluble guanylyl cyclase. Redox modification of thiols by 
GSNO on PDI and other thiol containing proteins may be significant in mediating both 
cGMP-dependent and cGMP-independent antiplatelet actions of GSNO. In view of 
emerging evidence that integrin function and platelet aggregation are controlled by 
redox transitions occurring at the cell surface and catalysed by both PDI and other thiol 
isomerases, the interaction of GSNO with PDI in bringing about platelet inhibition takes 
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Figure 1. MEG-01 cell mediated metabolism of RSNO.  MEG-01 cells were incubated 
with 1 μM GSNO (figure 1a) or albSNO (figure 1b) at 37°C for 2 minutes following 
which residual RSNO was measured in supernatant (control sample). Effects of enzyme 
inhibitors were studied by incubating cells with acivicin (100 μM), DTNB (100 μM) or 
bacitracin (5 mM) for 30 minutes prior to addition of RSNO. Results shown are mean 
(SEM) from 3-6 separate experiments. *P < 0.05, compared with control. 
 
Figure 2. Inhibition of platelet aggregation by RSNO. Washed platelets were pre-
incubated with 1 μM GSNO or albSNO for 5 or 30 seconds prior to addition of 
thrombin (0.1 units ml -1) to induce platelet aggregation. Aggregation was monitored 
turbidometrically over 2 minutes. GSNO was able to almost completely inhibit 
thrombin induced platelet aggregation within 5 seconds. However, albSNO only 
partially inhibited platelet aggregation. Values are expressed as mean (SEM) (n = 4). 
 
Figure 3. cGMP accumulation in response to RSNO. MEG-01 cells were incubated with 
GSNO or albSNO (both 1 μM) for 2 minutes, following which cGMP levels were 
analysed using enzyme immunoassay (figure 3a). Effects of enzymes or surface thiols 
were analysed by treatment of MEG-01 cells with inhibitors for 30 minutes at 37°C prior 
to addition of GSNO (1 μM) (figure 3b). Results shown are mean (SEM) from 6 separate 
experiments *P < 0.05 compared with control. 
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Figure 4. Effect of GSNO on PDI activity in MEG-01 cell supernatant. GSNO (0 – 500 
μM) was incubated with supernatant for 30 minutes prior to addition of insulin 
substrate. PDI activity was then monitored by measuring the increase in turbidity (at 
650 nm) over a period of 40 hours. Results shown are mean values for 4 - 6 
experiments.  
 
Figure 5. Redox modification of cell surface thiol-containing proteins by GSNO.  
MEG-01 cells were labelled with impermeable thiol specific probe, MPB (100 μM), 
cells were lysed and samples were run using 10 % SDS polyacrylamide gel under non-
reducing conditions. Samples were then transferred to a nitrocellulose membrane and 
protein thiols were detected with streptavidin-HRP. A number of thiol containing 
proteins were labelled on the MEG-01 cell surface (lane 1). Pre-incubation of cells with 
GSNO (3.5 mM) resulted in loss of thiol reactivity on several proteins, shown by arrows 
(lane 2). Results shown are representative of 3 similar experiments. 
 
Figure 6. Thiol modification of cell surface PDI by GSNO.  
Cell surface thiol labelling with MPB was performed as previously described.  Cells 
were treated with graded GSNO concentrations (0 – 5 mM) prior to labelling with MPB. 
Cells were then lysed and PDI was immunoprecipitated using a monoclonal antibody 
(RL 90) (4.2 μg ml-1). Control experiments were performed using an isotype control 
antibody.  Results shown are representative of 3 similar experiments. 
 
Figure 7. Reversal of GSNO-mediated thiol modification by GSH. 
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MEG-01 cells were treated with GSNO (4 mM) to modify surface thiols, after which 
they were washed and exposed to GSH (4 mM). MPB labelling was carried out as 
previously described and PDI immunoprecipitated using RL 90 monoclonal antibody. 
Lane 1 - Untreated cells; Lane 2 - Cells treated with GSNO; Lane 3 - Cells treated with 
GSH; Lane 4 - Cells treated with GSNO followed by GSH. 
  
 
 
